DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 206940
NDA 206940 describes VIBERZI, which is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug. Additional details are available on the VIBERZI profile page.
The generic ingredient in VIBERZI is eluxadoline. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the eluxadoline profile page.
The generic ingredient in VIBERZI is eluxadoline. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the eluxadoline profile page.
Summary for 206940
| Tradename: | VIBERZI |
| Applicant: | Allergan Holdings |
| Ingredient: | eluxadoline |
| Patents: | 12 |
Pharmacology for NDA: 206940
| Mechanism of Action | Opioid mu-Receptor Agonists |
Suppliers and Packaging for NDA: 206940
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VIBERZI | eluxadoline | TABLET;ORAL | 206940 | NDA | Allergan, Inc. | 61874-075 | N | 61874-075-60 |
| VIBERZI | eluxadoline | TABLET;ORAL | 206940 | NDA | Allergan, Inc. | 61874-100 | N | 61874-100-60 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 75MG | ||||
| Approval Date: | May 27, 2015 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | May 27, 2020 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | ➤ Try a Free Trial | Patent Expiration: | Mar 25, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | ➤ Try a Free Trial | Patent Expiration: | Mar 14, 2025 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Complete Access Available with Subscription
